To IPD or not to IPD?
Authors:
- Lesley A. StewartLSLesley A. Stewart
Top Cited Papers
- 1 March 2002
- journal article
- research article
- Published by SAGE Publications in Evaluation & the Health Professions
- Vol. 25 (1) , 76-97
Abstract
Systematic reviews and meta-analyses that obtain original research data on individual participants enrolled in trials have been described as the gold standard of review. However, they may take longer and be more resource intensive than other types of review. The authors describe potential advantages and disadvantages of the individual patient data (IPD) approach, including benefits from improved data quality, benefits afforded by the type of analyses that can be done, and advantages in achieving consensus around results and interpretation by an international multi disciplinary team. Disadvantages and barriers relating to resource and expertise, negotiating collaboration, and software requirements are also discussed. At the outset, reviewers should consider the methodological factors likely to influence results in their particular review setting, together with time and resource constraints, so that an active decision can be made about whether to extract data frompublished reports, collect addi tional or replacement summary data from trialists, or collect IPD.Keywords
This publication has 28 references indexed in Scilit:
- Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trialsBritish Journal of Cancer, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Improving the Quality of Reporting of Randomized Controlled TrialsJAMA, 1996
- The Cochrane Collaboration: Preparing, Maintaining, and Disseminating Systematic Reviews of the Effects of Health CareAnnals of the New York Academy of Sciences, 1993
- Factors Influencing Publication of Research ResultsJAMA, 1992
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991
- Publication bias in clinical researchThe Lancet, 1991
- The Existence of Publication Bias and Risk Factors for Its OccurrenceJAMA, 1990
- Randomisation and baseline comparisons in clinical trialsThe Lancet, 1990
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988